Teng C P, Chen H H, Chan J, Lye D C B
Department of Pharmacy, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, 308433 Singapore.
Int J Antimicrob Agents. 2007 Oct;30(4):356-9. doi: 10.1016/j.ijantimicag.2007.05.016. Epub 2007 Jul 13.
Ertapenem is indicated for complicated intra-abdominal, skin and skin-structure, urinary tract and acute pelvic infections as well as community-acquired pneumonia, for which there are cheaper and more narrow-spectrum antibiotics. It is active against extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria, but report of its clinical efficacy is lacking. We evaluated our experience with the use of ertapenem for ESBL-producing Gram-negative bacterial infections over 13 months. Forty-seven patients were treated with 50 courses of ertapenem. Thirty-nine courses were for ESBL-producing Gram-negative bacterial infections, 33% of which were bacteraemia. The clinical response rate was 92% and survival to hospital discharge was 94%. We propose that ertapenem has a role in the first-line treatment of these infections.
厄他培南适用于复杂性腹腔内感染、皮肤及皮肤结构感染、泌尿系统感染、急性盆腔感染以及社区获得性肺炎，而针对这些疾病有更便宜且抗菌谱更窄的抗生素。它对产超广谱β-内酰胺酶（ESBL）的革兰阴性菌有活性，但缺乏其临床疗效的报道。我们评估了在13个月期间使用厄他培南治疗产ESBL革兰阴性菌感染的经验。47例患者接受了50个疗程的厄他培南治疗。39个疗程用于产ESBL革兰阴性菌感染，其中33%为菌血症。临床有效率为92%，出院生存率为94%。我们认为厄他培南在这些感染的一线治疗中具有一定作用。
